ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COG.GB Cambridge Cognition Holdings PLC

45.50
0.00 (0.00%)
17 May 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings PLC AQSE:COG.GB Aquis Stock Exchange Ordinary Share GB00B8DV9647
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 45.50 42.00 49.00 45.50 43.77 45.50 6,481 15:29:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Cambridge Cognition Holdings PLC Major contract win combining solutions (6994P)

11/10/2023 7:00am

UK Regulatory


Cambridge Cognition (AQSE:COG.GB)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Cambridge Cognition Charts.

TIDMCOG

RNS Number : 6994P

Cambridge Cognition Holdings PLC

11 October 2023

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Major contract win combining Cambridge Cognition

and Winterlight solutions

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a significant contract for a sizeable later stage clinical trial, following a competitive tender. The contract combines the Company's proprietary CANTAB(R) touch-screen cognitive assessments with verbal assessments from its recent Winterlight Labs acquisition, for the first time. Additionally, the Company will supply its electronic Clinical Outcome Assessments ("eCOA") and provide full training for clinicians, together with quality control services.

This initial contract is valued at approximately GBP1 million and revenue is expected to be recognised over a two-year period, starting in 2023. There is potential for a further contract with the same customer, of slightly higher value, in 2024 once the initial results have been analysed from this trial.

Cambridge Cognition and its Winterlight business are recognised as world leaders in accurate cognitive assessment for neurodegenerative disease trials. Having acquired Winterlight in January 2023, Cambridge Cognition developed an integrated front-end within the first few months post-acquisition and now offers the broadest proprietary solution for touchscreen and voice assessments in clinical trials. Cambridge Cognition is the only company that can offer this unique set of cognitive assessments and eCOA as a single vendor solution.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition said:

"Cambridge Cognition acquired Winterlight to have the broadest offering on the market. With this contract win, we are realising the benefits of the acquisition. We're excited to be providing full clinical assessment services for a large clinical trial to a new customer, that we would have been unlikely to win without having made the Winterlight acquisition. We can expect to win more contracts like this over time as we continue to commercialise the combined solutions."

Enquiries

 
Cambridge Cognition Holdings Plc              Tel: 012 2381 0700 
 Matthew Stork, Chief Executive Officer        press@camcog.com 
 Stephen Symonds, Chief Financial Officer 
Panmure Gordon (UK) Limited (NOMAD and Joint  Tel: 020 7886 2500 
 Broker)                                       (Corporate Finance) 
 Freddy Crossley / Emma Earl                   (Corporate Broking) 
 Rupert Dearden 
Dowgate Capital Limited (Joint Broker)        Tel: 020 3903 7715 
 David Poutney / James Serjeant 
IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
 Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTDZMMGRGVGFZM

(END) Dow Jones Newswires

October 11, 2023 02:00 ET (06:00 GMT)

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock